BBIO BridgeBio Pharma Inc.

28.38
+1.45  (+5%)
Previous Close 26.93
Open 27.6
Price To Book 8.6
Market Cap 3,512,463,897
Shares 123,765,465
Volume 1,088,870
Short Ratio
Av. Daily Volume 1,069,900
Stock charts supplied by TradingView

NewsSee all news

  1. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the

  2. BridgeBio Pharma's QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

    PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or

  3. BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

    PALO ALTO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today the pricing of $475 million aggregate principal amount of 2.50%

  4. BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

    PALO ALTO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today that it intends to offer, subject to market conditions and other factors,

  5. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 2, 2020, the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2021.
AG10 / BBP-265 - ATTRibute-CM
ATTR-CM
Phase 3 trial planned for 1H 2020.
AG10 / BBP-265
ATTR-PN
Phase 2 pivotal trial data due 2H 2020.
BBP-831 (infigratinib)
Cholangiocarcinoma
Phase 2 dosing to commence in the coming months - noted March 2, 2020.
BBP-831 (PROPEL2)
Achondroplasia
Phase 3 completion of enrolment announced December 2, 2019.
BBP-009/Patidegib
Gorlin syndrome
Phase 2 trial initiation announced January 8, 2020.
BBP-009/Patidegib
High-Frequency Basal Cell Carcinoma
Rolling NDA initiation announced December 3, 2019.
Fosdenopterin (BBP-870/ORGN001)
Molybdenum cofactor deficiency type A
Phase 1/2 data due 2020.
BBP-589
Epidermolysis bullosa
Phase 2 trial to be initiated early 2020 with data due 2021.
Encaleret
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Phase 3 trial initiation announced March 12, 2020.
Infigratinib (PROOF 302)
Urothelial Carcinoma
Phase 2 trial initiation announced March 12, 2020.
Infigratinib
Solid tumors

Latest News

  1. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the

  2. BridgeBio Pharma's QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

    PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or

  3. BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

    PALO ALTO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today the pricing of $475 million aggregate principal amount of 2.50%

  4. BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

    PALO ALTO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today that it intends to offer, subject to market conditions and other factors,

  5. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 2, 2020, the

  6. BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

    -Achieved multiple clinical and pre-clinical milestones across BridgeBio's pipeline -Delivered pipeline expansion with addition of five new drug development and discovery programs; BridgeBio's portfolio now includes

  7. BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors

    PALO ALTO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president

  8. BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

    PALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), together with affiliate company Eidos Therapeutics (NASDAQ:EIDX) announced today that they are presenting at two upcoming

  9. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 3, 2020, the

  10. BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

    SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines.

  11. BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

    The deal is designed to accelerate BridgeBio's gene therapy programsThe dedicated suite will support clinical and commercial supply needs for BridgeBio's gene therapy programs for congenital adrenal hyperplasia (BBP-631)

  12. PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma

    PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with

  13. BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

    SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with first-line advanced or

  14. BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference

    PALO ALTO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3 PM

  15. BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

    BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD)

  16. BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

    PALO ALTO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable expertise as a

  17. BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

    PALO ALTO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli Wallace, Ph.D., as its

  18. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the

  19. BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

    BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug

  20. PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

    - Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment

  21. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its

  22. BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

    AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)

  23. BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

    Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2iEnded quarter with $446.1 million in

  24. Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

    SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third

  25. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  26. Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

    PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,